Abstract
Background: Mild cognitive deficits are more likely to occur with increasing age, and become more pronounced for people diagnosed with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Conventional methods to identify cognitive declines (i.e., neuropsychological testing and clinical judgment) can lead to false positive diagnoses of cognitive impairment. Tools such as electroencephalography (EEG) offer additional measures of cognitive processing, indexing the electrophysiological changes associated with aging, MCI and AD.
Objective: We reviewed the literature on EEG to determine if auditory event-related potentials (ERPs) could distinguish between healthy aging, MCI, and AD.
Method: We searched two electronic databases (Medline and PyscInfo) for articles published between January 2005 and April 2017. Articles were considered for review if they included: i) participants 60 years of age or older; ii) healthy older adults or those diagnosed with MCI or AD; iii) at least one auditory elicited ERP component.
Results: Our search revealed 1532 articles (800 after removing duplicates); 719 were excluded through title/abstract review, and of the 81 remaining articles, 30 satisfied inclusion criteria. All studies compared cognitive function between at least two of the three selected populations. Our findings suggest that the P300 and N200 components may distinguish between healthy cognitive aging, MCI, and AD.
Conclusion: ERPs may be sensitive to progressive cognitive changes due to MCI and AD. The P300 and N200 may help identify patients who are likely to progress from MCI to AD, and could be a valuable clinical tool.
Keywords: Alzheimer's disease, event-related potentials, mild cognitive impairment, P50, N100, P100, N200, P300.
Current Alzheimer Research
Title:Auditory Event-related Potentials in Mild Cognitive Impairment and Alzheimer’s Disease
Volume: 15 Issue: 8
Author(s): Cassandra Morrison*, Sheida Rabipour, Frank Knoefel, Christine Sheppard and Vanessa Taler
Affiliation:
- School of Psychology, University of Ottawa, Ottawa, ON, Canada, Bruyère Research Institute, Ottawa, ON,Canada
Keywords: Alzheimer's disease, event-related potentials, mild cognitive impairment, P50, N100, P100, N200, P300.
Abstract: Background: Mild cognitive deficits are more likely to occur with increasing age, and become more pronounced for people diagnosed with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Conventional methods to identify cognitive declines (i.e., neuropsychological testing and clinical judgment) can lead to false positive diagnoses of cognitive impairment. Tools such as electroencephalography (EEG) offer additional measures of cognitive processing, indexing the electrophysiological changes associated with aging, MCI and AD.
Objective: We reviewed the literature on EEG to determine if auditory event-related potentials (ERPs) could distinguish between healthy aging, MCI, and AD.
Method: We searched two electronic databases (Medline and PyscInfo) for articles published between January 2005 and April 2017. Articles were considered for review if they included: i) participants 60 years of age or older; ii) healthy older adults or those diagnosed with MCI or AD; iii) at least one auditory elicited ERP component.
Results: Our search revealed 1532 articles (800 after removing duplicates); 719 were excluded through title/abstract review, and of the 81 remaining articles, 30 satisfied inclusion criteria. All studies compared cognitive function between at least two of the three selected populations. Our findings suggest that the P300 and N200 components may distinguish between healthy cognitive aging, MCI, and AD.
Conclusion: ERPs may be sensitive to progressive cognitive changes due to MCI and AD. The P300 and N200 may help identify patients who are likely to progress from MCI to AD, and could be a valuable clinical tool.
Export Options
About this article
Cite this article as:
Morrison Cassandra*, Rabipour Sheida , Knoefel Frank , Sheppard Christine and Taler Vanessa , Auditory Event-related Potentials in Mild Cognitive Impairment and Alzheimer’s Disease, Current Alzheimer Research 2018; 15 (8) . https://dx.doi.org/10.2174/1567205015666180123123209
DOI https://dx.doi.org/10.2174/1567205015666180123123209 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Millennium Nutrient N,N-Dimethylglycine (DMG) and its Effectiveness
in Autism Spectrum Disorders
Current Medicinal Chemistry An Overview of Galenic Preparation Methods for Medicinal Cannabis
Current Bioactive Compounds Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets Role of Positron Emission Tomography for Central Nervous System Involvement in Systemic Autoimmune Diseases: Status and Perspectives
Current Medicinal Chemistry Warfarin Dosing and the Promise of Pharmacogenomics
Current Clinical Pharmacology The Sustained Effects on Tear Volume of Pilocarpine Hydrochloride in Gelatin by Hydrogel Administered by An Implant-mediated Drug Delivery System
Current Drug Delivery Nutritional and Pharmacological Management of Childhood Epilepsy: Ketogenic Diets and Common AEDs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Editorial (Thematic Issue: Neurology and Genetics: How Molecular Biology is Changing the Neurological Thoughts?)
Current Molecular Medicine Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers
Mini-Reviews in Medicinal Chemistry MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design α7-Nicotinic Acetylcholine Receptors: An Old Actor for New Different Roles
Current Drug Targets Editorial (Thematic Selection: Special Issue on Metabotropic Glutamate Receptors)
Current Neuropharmacology Video Game Addiction: Past, Present and Future
Current Psychiatry Reviews Advanced Intraoperative MR Imaging
Current Medical Imaging Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics Inflammatory Process in Parkinsons Disease: Role for Cytokines
Current Pharmaceutical Design Pharmacological Intervention at Ionotropic Glutamate Receptor Complexes
Current Pharmaceutical Design Mitochondriotropic Cationic Vesicles A Strategy Towards Mitochondrial Gene Therapy
Current Pharmaceutical Biotechnology